{"filing":{"accession_number":"0001193125-26-426828","cik":"0001824893","ticker":"SRZNW","company_name":"Surrozen, Inc./DE","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"srzn-20261020.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1824893/000119312526426828/srzn-20261020.htm"},"events":[{"id":36488,"run_id":33644,"accession_number":"0001193125-26-426828","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Surrozen completed the second tranche of a private placement on October 20, 2026, issuing approximately 5.7 million shares of common stock, 2.5 million pre-funded warrants, and 4.1 million Series E common warrants for approximately $95.1 million in gross proceeds. This unregistered equity issuance under Section 4(a)(2) and Regulation D generates substantial dilution to existing shareholders.","company_name":"Surrozen, Inc./DE","ticker":"SRZNW","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40919,"accession_number":"0001193125-26-426828","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the closing of the second tranche of a private placement generating $95.1 million in gross proceeds through issuance of approximately 5.7 million shares of common stock, 2.5 million pre-funded warrants, and 4.1 million Series E common stock warrants. This is a material dilutive equity issuance typical of biotechnology companies raising capital, with significant warrant dilution that substantially increases the outstanding share count and potential dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T21:05:46.930904+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40920,"accession_number":"0001193125-26-426828","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Surrozen completed the second tranche of a private placement on October 20, 2026, issuing 5,741,605 shares of common stock, 2,456,500 pre-funded warrants, and 4,099,052 Series E common warrants for approximately $95.1 million in gross proceeds. This is a classic unregistered equity issuance under Section 4(a)(2) and Regulation D, disclosed under Item 3.02, generating substantial dilution to existing shareholders and raising material capital for the biotechnology company's clinical development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T21:05:46.930904+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40919,"accession_number":"0001193125-26-426828","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the closing of the second tranche of a private placement generating $95.1 million in gross proceeds through issuance of approximately 5.7 million shares of common stock, 2.5 million pre-funded warrants, and 4.1 million Series E common stock warrants. This is a material dilutive equity issuance typical of biotechnology companies raising capital, with significant warrant dilution that substantially increases the outstanding share count and potential dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T21:05:46.930904+00:00","company_name":"Surrozen, Inc./DE","ticker":"SRZNW","filing_date":"2026-10-20"},{"id":40920,"accession_number":"0001193125-26-426828","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Surrozen completed the second tranche of a private placement on October 20, 2026, issuing 5,741,605 shares of common stock, 2,456,500 pre-funded warrants, and 4,099,052 Series E common warrants for approximately $95.1 million in gross proceeds. This is a classic unregistered equity issuance under Section 4(a)(2) and Regulation D, disclosed under Item 3.02, generating substantial dilution to existing shareholders and raising material capital for the biotechnology company's clinical development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T21:05:46.930904+00:00","company_name":"Surrozen, Inc./DE","ticker":"SRZNW","filing_date":"2026-10-20"}]}